Brief: HLS Therapeutics Files New Drug Submission For Perseris In Canada
23/01/2020 11:32
Jan 23 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS FILES NEW DRUG SUBMISSION FOR PERSERIS®
IN
CANADA
* HLS THERAPEUTICS INC - HLS IS SEEKING APPROVAL FOR
PERSERIS WITH
AN INDICATION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
* HLS THERAPEUTICS INC - NEW DRUG SUBMISSION FOR PERSERIS
WAS
ACCEPTED FOR REVIEW BY HEALTH CANADA ON JAN 23, 2020
Source text for Eikon: ID:nCNW1jcdja
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease